Collaborations- from MD&AHere are some interesting updates that confirms what many has suspected. Shire- time waster. Medimmune- checked. Abbvie/ UCB- in discussion.
3/4- not too bad..plus any other new players as outlined in JD's post.
looking good.
h
Shire Human Genetic Therapies Inc.
On November 24, 2011, the Company announced that it had entered into a research, evaluation
and option agreement with Shire Human Genetic Therapies, Inc. (Shire) to evaluate biOasis’s
Transcend technology in the area of lysosomal storage disorders. In connection with this
agreement, biOasis and Shire undertook certain experiments at their own expense and Shire had
certain rights that have now expired. The companies plan no further studies or programs at this
time.
AbbVie Inc.
On June 18, 2012, the Company announced a research, evaluation and option agreement with
Abbott Laboratories. In consideration for entering into this agreement, undertaking certain
activities and funding a number of experiments, Abbott was granted certain options to obtain a
license to Transcend technology under mutually agreeable terms. On November 28, 2012
Abbott announced the separation of its research-based pharmaceuticals business, which is now
called AbbVie Inc. The companies are currently in discussions regarding potential future
research/work programs.
Medimmune Limited
On November 14, 2012, we announced that biOasis had entered into a research and evaluation
agreement with Medimmune Limited (“Medimmune”), the global biologics arm of AstraZeneca.
Under the terms of that collaboration, biOasis conducted certain experiments at MedImmune’s
expense with the objective of demonstrating that biOasis’s Transcend technology can deliver to
the brain compounds of interest to MedImmune.
On March 17, 2014 we announced that biOasis has signed an evaluation and license agreement
with MedImmune. Under the terms of the agreement, MedImmune will evaluate the therapeutic
effect of its pre-clinical assets with next-generation versions (initially Transcendpep) of biOasis’s
Transcend brain delivery platform.
UCB Pharma SA
On December 3, 2012 we announced that the Company had entered into a research collaboration
agreement with Brussels, Belgium-based UCB Pharma SA (UCB). In connection with this
agreement, biOasis is conducting certain experiments to provide UCB with confirmation of the
Transcend technology as it relates to the delivery to the brain of therapeutic compounds owned
by UCB. The companies are in discussions regarding the potential introduction of the
Transcendpep program into the UCB work program.